The interplay between surfaces and soluble factors define the immunologic and angiogenic properties of myeloid dendritic cells

BMC Immunology

Volumn 12, Issue , 2011, Pages

  Sprague, Leslee ^a   Muccioli, Maria ^b   Pate, Michelle ^c   Meles, Evan ^c   McGinty, John ^c   Nandigam, Harika ^a   Venkatesh, Amritha K ^a   Gu, Ming yu ^a   Mansfield, Kristen ^c   Rutowski, Andrew ^c   Omosebi, Omowaleola ^c   Courreges, Maria C ^c   Benencia, Fabian ^a,b,c  

^a Ohio University   (United States)

^b OHIO UNIVERSITY   (United States)

^c OHIO UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; COMPLEMENTARY DNA; FIBRONECTIN; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MATRIGEL; MESSENGER RNA; POLYLYSINE; POLYSTYRENE; VASCULOTROPIN; ANGIOGENIC PROTEIN; COLLAGEN; GELATIN; LAMININ; POLYSTYRENE DERIVATIVE; PROTEOGLYCAN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; BONE MARROW CELL; CELL CULTURE; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MICROENVIRONMENT; MOUSE; NONHUMAN; OVARY CANCER; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR; T LYMPHOCYTE; ANIMAL; C57BL MOUSE; CULTURE TECHNIQUE; DRUG COMBINATION; DRUG EFFECT; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METHODOLOGY; PHYSIOLOGY; SECRETION; TUMOR CELL LINE;

ANGIOGENIC PROTEINS; ANIMALS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; COLLAGEN; COLLAGEN TYPE I; DENDRITIC CELLS; DRUG COMBINATIONS; FEMALE; FIBRONECTINS; GELATIN; LAMININ; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MYELOID CELLS; POLYLYSINE; POLYSTYRENES; PROTEOGLYCANS; T-LYMPHOCYTES;

EID: 79957895557     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-12-35     Document Type: Article

References (72)

1. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18:767-811. 10.1146/annurev.immunol.18.1.767, 10837075.
2. Bonasio R, von Andrian UH. Generation, migration and function of circulating dendritic cells. Curr Opin Immunol 2006, 18(4):503-511. 10.1016/j.coi.2006.05.011, 16777395.
3. Lanzavecchia A, Sallusto F. The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Curr Opin Immunol 2001, 13:291-298. 10.1016/S0952-7915(00)00218-1, 11406360.
4. Breckpot K, Escors D. Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification. Endocr Metab Immune Disord Drug Targets 2009, 9(4):328-343. 2797000, 19857199.
5. Diebold SS, Montoya M, Unger H, Alexopoulou L, Roy P, Haswell LE, Al-Shamkhani A, Flavell R, Borrow P, Reis e Sousa C. Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 2003, 424(6946):324-328. 10.1038/nature01783, 12819664.
6. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005, 23:275-306. 10.1146/annurev.immunol.23.021704.115633, 15771572.
7. Bluth MJ, Zaba LC, Moussai D, Suarez-Farinas M, Kaporis H, Fan L, Pierson KC, White TR, Pitts-Kiefer A, Fuentes-Duculan J, Guttman-Yassky E, Krueger JG, Lowes MA, Carucci JA. Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation. J Invest Dermatol 2009, 129(10):2451-2462. 10.1038/jid.2009.96, 2846605, 19387481.
8. Banerjee DK, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar KM. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 2006, 108(8):2655-2661. 10.1182/blood-2006-03-011353, 1895594, 16763205.
9. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996, 2(10):1096-1103. 10.1038/nm1096-1096, 8837607.
10. Tian F, Grimaldo S, Fujita M, Cutts J, Vujanovic NL, Li LY. The endothelial cell-produced antiangiogenic cytokine vascular endothelial growth inhibitor induces dendritic cell maturation. J Immunol 2007, 179(6):3742-3751.
11. Vicari AP, Chiodoni C, Vaure C, Ait-Yahia S, Dercamp C, Matsos F, Reynard O, Taverne C, Merle P, Colombo MP, O'Garra A, Trinchieri G, Caux C. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002, 196(4):541-549. 10.1084/jem.20020732, 2196048, 12186845.
12. Conejo-Garcia JR, Benencia F, Courreges MC, Kang E, Mohamed-Hadley A, Buckanovich RJ, Holtz DO, Jenkins A, Na H, Zhang L, Wagner DS, Katsaros D, Caroll R, Coukos G. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 2004, 10(9):950-958. 10.1038/nm1097, 15334073.
13. Mantovani A, Sozzani S, Locati M, Schioppa T, Saccani A, Allavena P, Sica A. Infiltration of tumours by macrophages and dendritic cells: tumour-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Novartis Found Symp 2004, 256:137-145. discussion 146-138, 259-169.
14. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002, 282(5):C947-970.
15. Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-Hogan M, Wei S, Zou L, Kryczek I, Hoyle G, Lackner A, Carmeliet P, Zou W. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 2004, 64(16):5535-5538. 10.1158/0008-5472.CAN-04-1272, 15313886.
16. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999, 223(1):77-92. 10.1016/S0022-1759(98)00204-X, 10037236.
17. Lutz MB, Schnare M, Menges M, Rossner S, Rollinghoff M, Schuler G, Gessner A. Differential functions of IL-4 receptor types I and II for dendritic cell maturation and IL-12 production and their dependency on GM-CSF. J Immunol 2002, 169(7):3574-3580.
18. Zhang L, Yang N, Garcia JR, Mohamed A, Benencia F, Rubin SC, Allman D, Coukos G. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol 2002, 161(6):2295-2309. 10.1016/S0002-9440(10)64505-1, 1850900, 12466143.
19. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, Persons DL, Smith PG, Terranova PF. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000, 21(4):585-591. 10.1093/carcin/21.4.585, 10753190.
20. Zhang L, Conejo-Garcia JR, Yang N, Huang W, Mohamed-Hadley A, Yao W, Benencia F, Coukos G. Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in murine ovarian cancer cells. Biochem Biophys Res Commun 2002, 292(4):860-868. 10.1006/bbrc.2002.6710, 11944893.
21. Benencia F, Courreges MC, Conejo-Garcia JR, Mohamed-Hadley A, Zhang L, Buckanovich RJ, Carroll R, Fraser N, Coukos G. HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol Ther 2005, 12(5):789-802. 10.1016/j.ymthe.2005.03.026, 15925544.
22. Schweizerhof M, Stosser S, Kurejova M, Njoo C, Gangadharan V, Agarwal N, Schmelz M, Bali KK, Michalski CW, Brugger S, Dickenson A, Simone DA, Kuner R. Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain. Nat Med 2009, 15(7):802-807. 10.1038/nm.1976, 19525966.
23. Benencia F, Courreges MC, Fraser NW, Coukos G. Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer Biol Ther 2008, 7(8):1194-1205. 10.4161/cbt.7.8.6216, 18458533.
24. Conejo-Garcia JR, Buckanovich RJ, Benencia F, Courreges MC, Rubin SC, Carroll RG, Coukos G. Vascular leukocytes contribute to tumor vascularization. Blood 2005, 105(2):679-681. 10.1182/blood-2004-05-1906, 15358628.
25. Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, Katsaros D, O'Brien-Jenkins A, Gimotty PA, Coukos G. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008, 14(1):28-36. 10.1038/nm1699, 18157142.
26. Gotsman I, Sharpe AH, Lichtman AH. T-cell costimulation and coinhibition in atherosclerosis. Circ Res 2008, 103(11):1220-1231. 10.1161/CIRCRESAHA.108.182428, 2662382, 19028921.
27. McCarthy DA, Macey MG, Bedford PA, Knight SC, Dumonde DC, Brown KA. Adhesion molecules are upregulated on dendritic cells isolated from human blood. Immunology 1997, 92(2):244-251. 10.1046/j.1365-2567.1997.00346.x, 1364065, 9415033.
28. Carlow DA, Gossens K, Naus S, Veerman KM, Seo W, Ziltener HJ. PSGL-1 function in immunity and steady state homeostasis. Immunol Rev 2009, 230(1):75-96. 10.1111/j.1600-065X.2009.00797.x, 19594630.
29. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 2004, 199:251-263. 10.1111/j.0105-2896.2004.00139.x, 15233739.
30. Grolleau-Julius A, Abernathy L, Harning E, Yung RL. Mechanisms of murine dendritic cell antitumor dysfunction in aging. Cancer Immunol Immunother 2009, 58(12):1935-1939. 10.1007/s00262-008-0636-9, 2773435, 19082999.
31. Macary PA, Too CT, Dai X. Targeting tumours by adoptive transfer of immune cells. Clin Exp Pharmacol Physiol 2006, 33(5-6):569-574. 10.1111/j.1440-1681.2006.04409.x, 16700896.
32. Bianco NR, Kim SH, Morelli AE, Robbins PD. Modulation of the immune response using dendritic cell-derived exosomes. Methods Mol Biol 2007, 380:443-455. 10.1007/978-1-59745-395-0_28, 17876111.
33. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008, 8(8):618-631. 10.1038/nrc2444, 18633355.
34. Simon JC, Hara H, Denfeld RW, Martin S. UVB-irradiated dendritic cells induce nonproliferating, regulatory type T cells. Skin Pharmacol Appl Skin Physiol 2002, 15(5):330-334.
35. Yamagami S, Usui T, Amano S, Ebihara N. Bone marrow-derived cells in mouse and human cornea. Cornea 2005, 24(8 Suppl):S71-S74.
36. Yrlid U, Svensson M, Johansson C, Wick MJ. Salmonella infection of bone marrow-derived macrophages and dendritic cells: influence on antigen presentation and initiating an immune response. FEMS Immunol Med Microbiol 2000, 27(4):313-320. 10.1111/j.1574-695X.2000.tb01445.x, 10727887.
37. Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res 2010, 339(1):269-280. 10.1007/s00441-009-0834-6, 2784866, 19693543.
38. Ammon C, Meyer SP, Schwarzfischer L, Krause SW, Andreesen R, Kreutz M. Comparative analysis of integrin expression on monocyte-derived macrophages and monocyte-derived dendritic cells. Immunology 2000, 100(3):364-369. 10.1046/j.1365-2567.2000.00056.x, 2327027, 10929059.
39. Brand U, Bellinghausen I, Enk AH, Jonuleit H, Becker D, Knop J, Saloga J. Influence of extracellular matrix proteins on the development of cultured human dendritic cells. Eur J Immunol 1998, 28(5):1673-1680. 10.1002/(SICI)1521-4141(199805)28:05<1673::AID-IMMU1673>3.0.CO;2-J, 9603474.
40. Kohl K, Schnautz S, Pesch M, Klein E, Aumailley M, Bieber T, Koch S. Subpopulations of human dendritic cells display a distinct phenotype and bind differentially to proteins of the extracellular matrix. Eur J Cell Biol 2007, 86(11-12):719-730. 10.1016/j.ejcb.2007.06.007, 17689829.
41. Gottfried E, Kreutz M, Haffner S, Holler E, Iacobelli M, Andreesen R, Eissner G. Differentiation of human tumour-associated dendritic cells into endothelial-like cells: an alternative pathway of tumour angiogenesis. Scand J Immunol 2007, 65(4):329-335. 10.1111/j.1365-3083.2007.01903.x, 17386023.
42. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25(4):581-611. 10.1210/er.2003-0027, 15294883.
43. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005, 69(Suppl 3):11-16.
44. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9(6):669-676. 10.1038/nm0603-669, 12778165.
45. Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 2009, 9(5):639-651. 10.2174/156800909789057006, 19508171.
46. Dikov MM, Ohm JE, Ray N, Tchekneva EE, Burlison J, Moghanaki D, Nadaf S, Carbone DP. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol 2005, 174(1):215-222.
47. Scheeren RA, Koopman G, Van der Baan S, Meijer CJ, Pals ST. Adhesion receptors involved in clustering of blood dendritic cells and T lymphocytes. Eur J Immunol 1991, 21(5):1101-1105. 10.1002/eji.1830210503, 1709862.
48. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9(3):162-174. 10.1038/nri2506, 2828349, 19197294.
49. Kodelja V, Muller C, Tenorio S, Schebesch C, Orfanos CE, Goerdt S. Differences in angiogenic potential of classically vs alternatively activated macrophages. Immunobiology 1997, 197(5):478-493.
50. Gingis-Velitski S, Zetser A, Flugelman MY, Vlodavsky I, Ilan N. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 2004, 279(22):23536-23541. 10.1074/jbc.M400554200, 15044433.
51. Donohue PJ, Richards CM, Brown SA, Hanscom HN, Buschman J, Thangada S, Hla T, Williams MS, Winkles JA. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 2003, 23(4):594-600. 10.1161/01.ATV.0000062883.93715.37, 12615668.
52. Nakayama M, Harada N, Okumura K, Yagita H. Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies. Biochem Biophys Res Commun 2003, 306(4):819-825. 10.1016/S0006-291X(03)01051-9, 12821115.
53. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008, 66(1):1-9. 10.1016/j.critrevonc.2007.07.004, 17913510.
54. Benencia F, Courreges MC, Conejo-Garcia JR, Buckanovich RJ, Zhang L, Carroll RH, Morgan MA, Coukos G. Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma. Hum Gene Ther 2005, 16(6):765-778. 10.1089/hum.2005.16.765, 15960607.
55. Lewis CE, De Palma M, Naldini L. Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res 2007, 67(18):8429-8432. 10.1158/0008-5472.CAN-07-1684, 17875679.
56. Fernandez Pujol B, Lucibello FC, Gehling UM, Lindemann K, Weidner N, Zuzarte ML, Adamkiewicz J, Elsasser HP, Muller R, Havemann K. Endothelial-like cells derived from human CD14 positive monocytes. Differentiation 2000, 65(5):287-300. 10.1046/j.1432-0436.2000.6550287.x, 10929208.
57. Fernandez Pujol B, Lucibello FC, Zuzarte M, Lutjens P, Muller R, Havemann K. Dendritic cells derived from peripheral monocytes express endothelial markers and in the presence of angiogenic growth factors differentiate into endothelial-like cells. Eur J Cell Biol 2001, 80(1):99-110. 10.1078/0171-9335-00136, 11211940.
58. Fainaru O, Adini A, Benny O, Adini I, Short S, Bazinet L, Nakai K, Pravda E, Hornstein MD, D'Amato RJ, Folkman J. Dendritic cells support angiogenesis and promote lesion growth in a murine model of endometriosis. Faseb J 2008, 22(2):522-529.
59. Coukos G, Benencia F, Buckanovich RJ, Conejo-Garcia JR. The role of dendritic cell precursors in tumour vasculogenesis. Br J Cancer 2005, 92(7):1182-1187. 10.1038/sj.bjc.6602476, 2361965, 15785750.
60. Glod J, Kobiler D, Noel M, Koneru R, Lehrer S, Medina D, Maric D, Fine HA. Monocytes form a vascular barrier and participate in vessel repair after brain injury. Blood 2006, 107(3):940-946. 1895897, 16204319.
61. Sozzani S, Rusnati M, Riboldi E, Mitola S, Presta M. Dendritic cell-endothelial cell cross-talk in angiogenesis. Trends Immunol 2007, 28(9):385-392. 10.1016/j.it.2007.07.006, 17692569.
62. Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Buckanovich RJ, Benencia F, Stan RV, Keler T, Sarobe P, Sentman CL, Conejo-Garcia JR. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res 2008, 68(18):7684-7691. 10.1158/0008-5472.CAN-08-1167, 2742361, 18768667.
63. Nakai K, Fainaru O, Bazinet L, Pakneshan P, Benny O, Pravda E, Folkman J, D'Amato RJ. Dendritic cells augment choroidal neovascularization. Invest Ophthalmol Vis Sci 2008, 49(8):3666-3670. 10.1167/iovs.07-1640, 18408184.
64. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23(11):549-555. 10.1016/S1471-4906(02)02302-5, 12401408.
65. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999, 5(10):2963-2970.
66. Osada T, Chong G, Tansik R, Hong T, Spector N, Kumar R, Hurwitz HI, Dev I, Nixon AB, Lyerly HK, Clay T, Morse MA. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008, 57(8):1115-1124. 10.1007/s00262-007-0441-x, 18193223.
67. Heissig B, Nishida C, Tashiro Y, Sato Y, Ishihara M, Ohki M, Gritli I, Rosenkvist J, Hattori K. Role of neutrophil-derived matrix metalloproteinase-9 in tissue regeneration. Histol Histopathol 25(6):765-770.
68. Cubillos-Ruiz JR, Engle X, Scarlett UK, Martinez D, Barber A, Elgueta R, Wang L, Nesbeth Y, Durant Y, Gewirtz AT, Sentman CL, Kedl R, Conejo-Garcia JR. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest 2009, 119(8):2231-2244. 2719935, 19620771.
69. Cubillos-Ruiz JR, Fiering S, Conejo-Garcia JR. Nanomolecular targeting of dendritic cells for ovarian cancer therapy. Future Oncol 2009, 5(8):1189-1192. 10.2217/fon.09.101, 3056055, 19852731.
70. Bobryshev YV, Tran D, Killingsworth MC, Buckland M, Lord RV. Dendritic cell-associated immune inflammation of cardiac mucosa: a possible factor in the formation of Barrett's esophagus. J Gastrointest Surg 2009, 13(3):442-450. 10.1007/s11605-008-0746-x, 19015928.
71. Bobryshev YV, Lord RS. Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions. Cardiovasc Res 1998, 37(3):799-810. 10.1016/S0008-6363(97)00229-0, 9659465.
72. Yilmaz A, Lochno M, Traeg F, Cicha I, Reiss C, Stumpf C, Raaz D, Anger T, Amann K, Probst T, Ludwig J, Daniel WG, Garlichs CD. Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis 2004, 176(1):101-110. 10.1016/j.atherosclerosis.2004.04.027, 15306181.